Delcath Systems Inc (DCTH)

NASD · Healthcare · Medical Devices · USA

Delcath Systems Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.

Delcath Systems is an interventional oncology company that develops treatments for cancers primary or metastatic to the liver. The company's lead product, HEPZATO KIT, a drug-device combination approved by the FDA, treats uveal melanoma with unresectable hepatic metastases. In Europe, Delcath markets CHEMOSAT, a hepatic delivery system for melphalan, at major medical centers for various liver cancers.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Delcath Systems Inc stock.

Our verdict on DCTH

Overvalued: intrinsic value $5.21 per share, market price $19.37, margin of safety -271.7% (as of 2026-11-17).

Discounting its cash flows at 8.2% values the shares at $5.21; the price of $19.37 is 272% above that value.

ETFs with the most weight in DCTH

17 more funds hold it; the full list is part of the paid plan.

More on DCTH

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than DCTH in Medical Devices

46 more in this industry show a wider margin of safety.

Is DCTH undervalued or overvalued?

DCTH is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 8.2% values the shares at $5.21; the price of $19.37 is 272% above that value.

What is the intrinsic value of DCTH?

$5.21 per share (as of the 2026-11-17 close), against a market price of $19.37. That is a margin of safety of -271.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.